Navigation Links
Cardinal Health Reports Fiscal 2008 Results, Provides Fiscal 2009 Outlook
Date:8/7/2008

gies, where we delivered a year of very strong growth on the top and bottom lines. We also made steady progress throughout the year in our medical supply chain segment and, in particular, are very pleased with the results in our hospital, lab and ambulatory care distribution business.

"In our pharmaceutical supply chain segment, we believe we are on the right path to resolve the license suspensions that have kept us from distributing controlled substances from three of our 24 distribution centers. This will be a critical step in our efforts to drive improvements in the business. And while we won't speculate on the ultimate outcome, we are in constructive settlement discussions with the DEA and have recorded a reserve of $23.5 million in connection with those discussions. We have made good progress in enhancing our controls and are eager to return to full service levels for our customers."

Q4 and FY08 Summary

Q4 FY08 Q4 FY07 Y/Y FY08 Y/Y

Revenue $23 billion $22 billion 3% $91 billion 5%

Operating Earnings $543 million $421 million 29% $2.1 billion 55%

Non-GAAP Operating

Earnings(3) $568 million $538 million 6% $2.2 billion 3%

Earnings from

Continuing Operations $330 million $238 million 39% $1.3 billion 58%

Non-GAAP Earnings from

Continuing Operations $348 million $345 million 1% $1.4 billion -

Diluted EPS from

Continuing Operations $0.92 $0.61 51% $3.64 76%

Non-GAAP Diluted EPS from

Continuing Operations $0.97 $0.89 9% $3.80 11%

Fourth-quarter and full-year segment results

Revenue for the Healthcare Supply Chain Services - Pharmaceutical segment increased 1 percent to $19.8 billion for the quarter with sales to bulk customers increasing by 9 percent. Sales to non-bulk customers decrea
'/>"/>

SOURCE Cardinal Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Cardinal Health Declares Regular Quarterly Dividend
2. Cardinal Health Expands Leader(R) Offering To Help Independent Pharmacies Strengthen Patient Relationships, Solidify Role As Local Health Care Experts
3. Cardinal Health Formalizes Consolidation of Businesses Into Two Primary Operating and Reporting Segments
4. Cardinal Health Increases Quarterly Dividend by 17 Percent
5. Cardinal Health Reports Third Quarter Results
6. Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives
7. Cardinal Health to Announce Third-Quarter Results on May 1
8. Cardinal Health, ClearCount Medical Solutions Sign Primary Distribution Agreement for RFID-Enabled Sponge Counting, Detection System
9. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
10. Cardinal Health Names Former Acting Deputy U.S. Attorney General Craig S. Morford to Chief Compliance Officer Post
11. Cardinal Health Names Michael C. Kaufmann to Lead Pharmaceutical Segment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... essential fatty acids commonly found in fatty fish ... to research published by the American Psychological Association. ... problems found in people with schizophrenia; bipolar, obsessive-compulsive, ... afflictions of the nervous system. , The ... , provides more evidence that fish is brain ...
(Date:12/16/2009)... cut bleeding time in half, but use in humans is ... Hoping to improve on nature, researchers have built and tested ... used in trauma or other cases where blood just won,t ... material that is used in degradable stitches, which dissolve in ... engineering at Case Western Reserve University, and lead author of ...
(Date:12/16/2009)... Neurological Stress Reduction Therapy or NSRTSM is found very effective ... such as allergies, asthma, migraines, chronic fatigue and a wide ... the country are using this holistic therapy including over 50 ... ... Minneapolis, MN (Vocus) December 14, 2009 -- BioVeda ...
(Date:12/16/2009)... government report finds , , WEDNESDAY, Dec. 16 (HealthDay News) ... 45.4 million Americans of all ages -- or 15.1 ... according to new National Health Interview Survey statistics released ... of all ages had been uninsured for at least ... 31.9 million (10.6 percent) had been uninsured for more ...
(Date:12/16/2009)... Dec. 16 OrthoAccel Technologies, Inc., developers ... an acceleration device to enhance orthodontics, announced Alison ... the UK. Ms. Davies has spent the ... the dental industry, most recently for nine years ... , makers of Invisalign . ...
Breaking Medicine News(10 mins):Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5Health News:Over 45 Million Americans Now Lack Health Insurance 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4
... Accelerate Manufacture of Clinical Trial ... Pharmaceuticals, ... Michigan company specializing in winning FDA approval,for new drugs and medical ... award. RAA received the award for its development,of a fast-track process ...
... NATICK, Mass., Oct. 17 Boston Scientific,Corporation ... initiatives designed to,enhance short- and long-term shareholder value, ... as well as substantial expense and head,count reductions ... The,Company also said it is making good progress ...
... Oct. 17 GenPrime, Inc. a leading,provider of ... of its Bacterial Contamination Test for Platelets(TM). The,test ... presence of aerobic and,anaerobic bacteria commonly found in ... a 510 (K) pre-market notification with the Food,and ...
... ,Haemonetics Corporation (NYSE: HAE ) is pleased ... effective October 22, 2007 as President,Haemonetics Japan. Ms. ... who previously announced plans to retire. Brian ... tremendous experience and a proven track record for ...
... Address FDA,s Next Big Challenge, WASHINGTON, Oct. 17 ... information on drugs,and devices to physicians and the public?, ... will discuss and debate at a,landmark Colloquium, Communicating Risk/Safety ... Food and Drug Law Institute (FDLI),Dec. 6, 2007, in ...
... Kyphon Inc.,(Nasdaq: KYPH ) today announced ... and the Foundation for Osteoporosis Research,and Education (FORE) ... during World Osteoporosis Day on Saturday, October 20, ... go to: http://www.prnewswire.com/mnr/kyphon/29938/ To ...
Other Medicine News:Health News:Regulatory Affairs Associates Gets New Drugs Tested Faster, Wins 2007 Innovation Michigan Award 2Health News:Boston Scientific Announces New Initiatives to Increase Shareholder Value 2Health News:Boston Scientific Announces New Initiatives to Increase Shareholder Value 3Health News:Boston Scientific Announces New Initiatives to Increase Shareholder Value 4Health News:Boston Scientific Announces New Initiatives to Increase Shareholder Value 5Health News:GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets 2Health News:Keiko Hattori Joins Haemonetics as President of Haemonetics Japan 2Health News:Food and Drug Law Institute Sponsors Colloquium on Communicating Risk/Safety Drug Information 2Health News:Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk 2Health News:Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk 3
(Date:12/16/2009)... ALTO, Calif., Dec. 16 The Boards ... Corporation are delighted to announce the merger of ... the field of RNAi (RNA interference). The ... have multiple RNAi discovery, development and delivery technologies, ... a broad portfolio of intellectual property. ,, ...
(Date:12/16/2009)... 16 ChemoCentryx, Inc. today announced that ... 2 clinical trial of CCX354, an orally-bioavailable, novel, ... CCR1 chemokine receptor for the treatment of rheumatoid ... potent and selective antagonist of CCR1, a chemokine ... such as monocytes and macrophages, associated with the ...
(Date:12/15/2009)... ARDEE, Ireland, Dec. 15 Warner Chilcott ... its subsidiary Warner Chilcott Corporation (the "Company") has ... and subject to the conditions set forth in ... Statement dated December 15, 2009 (the "Offer to ... 8.75% senior subordinated notes due 2015 (the "Notes"). ...
Breaking Medicine Technology:Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 2Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 3Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 4Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 5Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 6Paul Marks prize recognizes 3 young cancer researchers 58437 1Paul Marks prize recognizes 3 young cancer researchers 58437 2Paul Marks prize recognizes 3 young cancer researchers 58437 3Paul Marks prize recognizes 3 young cancer researchers 58437 4Paul Marks prize recognizes 3 young cancer researchers 58437 5Women who make poor shoe choices at risk for foot pain later in life 58432 1Women who make poor shoe choices at risk for foot pain later in life 58432 2Katrina Hero Lt General Russel Honor 28Ret 29 to Speak on H1N1 Flu Preparedness at Press Briefing Following AmeriHealth Mercy PerformRx Conferenc 58430 1Katrina Hero Lt General Russel Honor 28Ret 29 to Speak on H1N1 Flu Preparedness at Press Briefing Following AmeriHealth Mercy PerformRx Conferenc 58430 2
... Unique monoclonal antibody successfully targets human leukemic stem ... Australia,s leading,biopharmaceutical company, has today presented data at ... which demonstrate the promising,pre-clinical activity of a novel ... leukemia (AML)., AML is an aggressive cancer ...
... Presentations Detail Progress with VeraTag(TM) Assays in Breast ... ... MGRM ) today announced five posters to be,presented at the 30th San ... 16, 2007. Following are details for,each embargoed session:, -- Friday, December ...
Other Medicine Technology:Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 3Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 2Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 3
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
Abbott offers an array of both in-vitro and molecular diagnostic tests for the detection and monitoring of cancerous conditions in patients....
... BrainSUITE iMRI is a neurosurgical OR ... and diagnostic tools, including iMRI, necessary ... BrainSUITE iMRI, neurosurgical treatments are performed ... and designed for MR compatibility and ...
... Quality EEG recording is assured even ... Neurofax has high performance, high sensitivity ... ECG rejection filter, shielded electrodes and a ... connection. Neurofax is a complete and ...
Medicine Products: